Benefits
Allergic rhinitis symptom relief
A landmark human RCT demonstrated Tinofend® (300 mg/day for 8 weeks) significantly reduced nasal discharge, sneezing, nasal obstruction, and nasal pruritis in patients with allergic rhinitis. 83% of patients showed improvement vs. 17% placebo — one of the strongest placebo-controlled results for a botanical in allergy research.
Immune system modulation
Tinospora polysaccharides activate macrophages and dendritic cells, increase NK cell activity, and modulate Th1/Th2 immune balance — shifting from the Th2-dominant state that drives allergic responses toward a more balanced immune profile. Used traditionally for recurrent infections and immune deficiency states.
Anti-inflammatory activity
Tinospora alkaloids and glycosides inhibit NF-κB activation, COX-2 expression, and prostaglandin production. Clinical studies show reductions in inflammatory markers in arthritis and metabolic disease patients with T. cordifolia supplementation.
Blood sugar regulation
Multiple studies show T. cordifolia extract reduces fasting blood glucose and improves insulin sensitivity in type 2 diabetic patients. Mechanisms include alpha-glucosidase inhibition, increased insulin secretion, and improved peripheral glucose utilization.
Adaptogenic and neuroprotective effects
T. cordifolia reduces cortisol levels, improves stress resilience, and protects neurons from oxidative and excitotoxic damage. The adaptogenic profile — reducing fatigue and improving stress response without sedation — is well-documented in Ayurvedic literature and emerging in modern research.
Mechanism of action
Macrophage and NK cell activation
Tinospora polysaccharides bind pattern recognition receptors (TLR-2, TLR-4, Dectin-1) on macrophages, triggering MyD88-dependent NF-κB activation and cytokine production. This innate immune priming increases NK cell cytotoxicity and accelerates pathogen clearance.
Th2-to-Th1 immune shifting
T. cordifolia extracts shift the cytokine balance from Th2 (allergic, IL-4, IL-5, IL-13-dominant) to Th1 (cellular, IFN-γ, IL-12-dominant) immune responses — directly opposing the immune dysregulation driving allergic rhinitis, asthma, and atopic dermatitis.
Alpha-glucosidase inhibition
Tinospora alkaloids and polysaccharides inhibit intestinal alpha-glucosidase enzyme activity, slowing carbohydrate digestion and glucose absorption — a direct antidiabetic mechanism shared with the pharmaceutical drug acarbose.
Clinical trials
Randomized, double-blind, placebo-controlled trial of Tinofend® (300 mg/day) vs. placebo in 75 patients with allergic rhinitis for 8 weeks.
75 adults with confirmed allergic rhinitis. 8-week intervention.
83% of Tinofend® patients showed clinically meaningful improvement in total nasal symptom score vs. 17% placebo. Significant reductions in sneezing, discharge, obstruction, and nasal pruritis. Excellent tolerability. Only human clinical trial for an Ayurvedic herb specifically for allergic rhinitis with this effect size.
Controlled clinical study of T. cordifolia stem powder supplementation in 60 type 2 diabetic patients for 3 months.
60 T2DM patients. 3-month intervention.
Significant reductions in fasting blood glucose, postprandial glucose, and HbA1c vs. control. Improved insulin sensitivity markers. No significant adverse effects. Supports adjunctive use in metabolic health.